Earendil Labs
AI-driven biotechnology for biologics
CORE INFO
Earendil Labs is a biotechnology company that uses artificial intelligence to accelerate the discovery and development of antibody-based therapeutics, targeting diseases like autoimmune disorders and cancer. Their innovative approach combines AI with experimental validation to design novel antibodies efficiently.
- Earendil Labs secured $787 million in financing in March 2026 from a consortium of global investors, including Dimension Capital, DST Global, and Sanofi, to enhance its AI-driven R&D platform.prnewswire.com
- The company has strategic collaborations with Sanofi for developing bispecific antibodies and with WuXi Biologics for manufacturing multispecific antibodies and ADCs.biospace.com
- The Medicine Maker highlighted Earendil Labs' $787 million financing as a blueprint for the evolving global structure of biotech companies.themedicinemaker.com
WHY WE WOULD WORK AT EARENDIL LABS
Innovative AI Technology
Join a team leveraging cutting-edge AI to revolutionize antibody-based therapeutics, expediting the journey from target identification to patient solutions.
Impactful Mission
Contribute to reshaping protein therapeutics discovery, improving patient outcomes globally through next-generation biologics.
Strong Funding Support
Be part of a well-funded venture with $787 million secured to enhance R&D capabilities and expand our biologics pipeline.
Collaborative Culture
Work alongside industry leaders and experts, including partnerships with Sanofi and WuXi Biologics, fostering a collaborative and innovative environment.
Career Growth Opportunities
With over 40 programs in development, including advanced clinical candidates, there are ample opportunities for professional growth and impact.
Cutting-Edge Research
Engage in high-throughput biology and experimental validation, utilizing AI-guided discovery to push the boundaries of biopharmaceutical research.
MARKET AND TRACTION
TOTAL ADDRESSABLE MARKET
KEY METRICS
✦ KEY METRICNOTABLE CUSTOMERS
GROWTH TACTICS
COMPETITIVE ADVANTAGE
PRODUCT AND TECH
Foundational Protein AI Platform
This platform utilizes deep learning models trained on sequence, structure, and interaction data to predict antibody-target binding and identify epitopes, enabling precise antibody design.
High-Throughput Biology Platform
Combining AI-guided discovery with experimental validation, this platform streamlines lead generation, screening, profiling, engineering, and production processes for antibody development.
Antibody-Based Therapeutics
Earendil Labs focuses on developing next-generation biologics, particularly antibody-based therapeutics, to address critical therapeutic areas such as autoimmune diseases and cancer.
Strategic Collaborations
The company has established partnerships with major players like Sanofi and WuXi Biologics to enhance the development and manufacturing of bispecific and multispecific antibodies, accelerating therapeutic solutions.
AI-Driven R&D Lifecycle
By integrating artificial intelligence throughout the research and development lifecycle, Earendil Labs aims to expedite the transition from target identification to therapeutic solutions for patients globally.